Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-01 10:58:54 - browse：8

Monica Bertagnolli -- Health Policy coverage from STAT — Dr. Monica Bertagnolli speaks during a visit from first lady Jill Biden to the University of California San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Friday, Oct. 7, 2022. (AP Photo/Jeff Chiu, Pool) Jeff Chiu/AP

WASHINGTON — Sen. Bernie Sanders (I-Vt.) will hold a confirmation hearing next month for Monica Bertagnolli, President Biden’s nominee to run the National Institutes of Health, he said Friday.

Sanders, whose health committee oversees the confirmation of the NIH nominee, had refused to hold a hearing on Bertagnolli until the Biden administration promised more drug pricing reform.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care.

Please enter a valid email address. Privacy Policy

HHS announced Friday a deal with Regeneron on the development of the Covid-19 monoclonal antibody. That deal seems to have satisfied Sanders’ demands, though Sanders said the administration must add reasonable pricing provisions to all drugs developed with the help of government funding.

“I welcome the Biden Administration’s announcement today that if Regeneron, through a $326 million contract recently signed with HHS, successfully develops a next generation monoclonal antibody for Covid-19 prevention, the list price of this drug must be equal to or lower than the price in other major countries,” Sanders said in a release.

Sen. Elizabeth Warren (D-Mass.) also had withheld support for Bertagnolli’s nomination until Bertagnolli agreed to Warren’s ethics demands. Bertagnolli agreed to not join the pharmaceutical industry or accept payment from the drug industry, until at least four years after leaving her government position.

Previous article： Medical records are filled with copy
Next article： Listen: More tumult at BIO & coercive care for sickle cell patients

focus

WSS

Questions and answers about ramping up H5N1 bird flu vaccine

FDA's Woodcock to retire early next year

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Study finds gene variants tied to breast cancer risk in Black women

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Listen: A conversation with researcher Kevin Esvelt on biosecurity

hotspot

Wikipedia

Sign up for D.C. Diagnosis

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Listen: More tumult at BIO & coercive care for sickle cell patients

Supreme Court strikes down use of affirmative action

Investigation reveals sickle cell patients pressured into sterilizations

In Memoriam: Notable people who died in 2023

PBM reforms clear House panel

Medicare details structure of new drug price negotiation program

A daunting task: navigating dual Medicare, Medicaid eligibility

Affirmative action in medical school literally saved lives

Morphosys mixed study results for blood cancer drug

Wikipedia

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Morphosys mixed study results for blood cancer drug

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

For longer

Anthos stroke drug appears safer than common blood thinner

Digital health: a case of mistaken identity

focus

focus

hotspot

Wikipedia